Key result
Rapidly evolving HF device therapies still lack robust evidence for newer technologies and specific indications.
Why the study?
Despite the rapid evolution of device therapy for heart failure, evidence remains lacking for newer technologies, common indications such as atrial fibrillation, and upgrading from previous devices.
Population
Patients with heart failure
Design
Review
Authors
Loading...
Evidence gaps warrant caution before adopting newer HF devices; leaves open need for targeted RCTs on indications.
Personalized medicine and rapid implementation of evolving device therapies and drugs are crucial for improving heart failure outcomes.
Cecilia Linde (2023) conducted a review in Heart failure. Device therapy (CRT, leadless pacing, conduction system pacing, ICD, CCM) was evaluated. Device therapies for heart failure, including CRT and conduction system pacing, have rapidly evolved, but evidence remains lacking for newer technologies and specific indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: